Search
Tramadol
go.drugbank.com/drugs/DB00193ApprovedInvestigationalTramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of actio...
Products: TRAMADOL-SAND 100MG/ML TROCX-051869
go.drugbank.com/drugs/DB31656ApprovedCX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1.
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawnRegdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.
Testosterone cypionate
go.drugbank.com/drugs/DB13943ApprovedInvestigationalIt was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.
CX-046684
go.drugbank.com/drugs/DB19414ApprovedCX-046684 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage KP.2.
Bamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigational[A224039, L15311, L15316] Bamlanivimab is a neutralizing IgG1κ mAb directed against the SARS-CoV-2 spike (S) protein, which is described to block viral entry into human cells.
Hydroxychloroquine
go.drugbank.com/drugs/DB01611ApprovedInvestigational[A183092] Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.
Sotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigationalSotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus.
Bebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawnIt binds to a portion of the SARS-CoV-2 spike (S) protein's receptor-binding domain, thereby preventing spike protein interaction with ACE2 and subsequent viral entry into host cells. … Bebtelovimab is notable in that the epitope to which it binds appears infrequently mutated, making it a viable candidate for use in resistant SARS-CoV-2 strains (i.e. variants of concern, VOCs), including
Davesomeran
go.drugbank.com/drugs/DB17091ApprovedInvestigational[L43882,L28026] However, with the addition of davesomeran, Moderna Bivalent vaccine offers protection against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants. … had previously received a two-dose primary series and one booster dose of Moderna COVID-19 Vaccine demonstrated that the Moderna Bivalent vaccine elicit a higher seroresponse both against the original SARS-CoV